BIOL 5597 — Immunotherapies of Cancer and Infectious Disease
4 semester hoursGraduateLectureusually offered: springBostonLive CastTraditional
Describes the basic principles and the current promises and disappointments with immunotherapies of cancer. Provides a historical overview of the main barriers between tumors and antitumor killer cells. The unifying focus of the lectures is the role of immunological and physiological negative regulators, i.e., “brakes” of anti-tumor immune response. A significant part of the course is dedicated to the retrospective evaluation of the last three decades of the immunological and biochemical studies that culminated in identification of the “chief of tumor defense operations,” i.e., a hypoxia-adenosinergic pathway in the tumor microenvironment.
Prerequisites
- one of:
- BIOL 2301 (min D-)
- graduate program admission
Offering history
| Term | Sections | Enrolled | Capacity | Full | Open seats/section |
|---|---|---|---|---|---|
| Spring 2024 | 1 | 38 | 40 | 95% | 2.0 |
| Spring 2025 | 1 | 37 | 40 | 93% | 3.0 |
| Spring 2026 | 1 | 38 | 40 | 95% | 2.0 |
Snapshots from scheduled scrapes — not live seat availability. "Full" can exceed 100% when sections over-enroll.
Meeting times
Share of recent sections by weekday: M 0% · T 34% · W 34% · Th 33% · F 34%
Common patterns: W (34% of sections), TF (34% of sections), R (33% of sections) — in patterns, R means Thursday
Professors
Spring
- Michail Sitkovsky (66% of students) · reviews
- Emeka Okeke (34% of students) · reviews
Percentages are each professor's average share of the season's enrolled students in recent terms.
Links
Official catalog (BIOL course descriptions) · Student reviews on RateMyHusky · All BIOL courses · Plan it at numap.app